Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00006591 |
Recruitment Status
: Unknown
Verified December 2004 by NIH AIDS Clinical Trials Information Service.
Recruitment status was: Active, not recruiting
First Posted
: August 31, 2001
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Ritonavir Drug: Amprenavir | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |
Official Title: | The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients may be eligible for this study if they:
- Are 18 years of age or older.
- Are HIV-positive.
- Have a viral load (level of HIV in the body) of more than 1,000 copies/ml.
- Have had more than 12 weeks of prior anti-HIV drug treatment.
- Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor.
- Are responsive to Agenerase.
- Are able to follow study requirements.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Are intolerant to ritonavir (an anti-HIV drug).
- Have or have had problems with absorption.
- Have liver disease or damage.
- Have pancreatic disease or damage.
- Have taken any protease inhibitor other than nelfinavir.
- Are receiving investigational drugs or devices from another study.
- Are pregnant or breast-feeding.
- Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide.
- Have a bleeding disorder.
- Have previously been treated with Agenerase.
- Are receiving nonnucleosides.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006591
United States, Texas | |
Gathe, Joseph, M.D. | |
Houston, Texas, United States, 77004 |
ClinicalTrials.gov Identifier: | NCT00006591 History of Changes |
Other Study ID Numbers: |
313A APV-430 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | December 2004 |
Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Therapy, Combination HIV Protease Inhibitors Ritonavir VX 478 Salvage Therapy |
Anti-HIV Agents Drug Monitoring Nelfinavir Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Amprenavir HIV Protease Inhibitors |
Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents |